Predictors of response to therapy with omalizumab in patients with severe allergic asthma – a real life study

References

• Global Initiative for Asthma. GINA workshop report, Global strategy for Asthma Management and prevention. Revised 2016, Available from http://www.ginasthma.org 2016.
   Google Scholar
• Holgate ST, Djukanovic R, Casale T, et al. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy. 2005;35:408–416. Epub 2005/04/20.
   PubMed Web of Science ®Google Scholar
• Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151:2623–2632. Epub 1993/09/01.
   PubMed Web of Science ®Google Scholar
• Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997;155:1828–1834. Epub 1997/06/01.
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004;59:701–708. Epub 2004/06/08.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60:302–308. Epub 2005/02/01.
   PubMed Web of Science ®Google Scholar
• Buhl R, Soler M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J. 2002;20:73–78. Epub 2002/08/09.
   PubMed Web of Science ®Google Scholar
• Chipps B, Buhl R, Beeh KM, et al. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin. 2006;22:2201–2208. Epub 2006/11/02.
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34:632–638. Epub 2004/04/15.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–316. Epub 2005/02/01.
   PubMed Web of Science ®Google Scholar
• Lanier BQ, Corren J, Lumry W, et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol. 2003;91:154–159. Epub 2003/09/04.
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254–261. Epub 2001/09/01.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011;66:671–678. Epub 2011/01/25.
   PubMed Web of Science ®Google Scholar
• Dewilde S, Turk F, Tambour M, et al. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin. 2006;22:1765–1776. Epub 2006/09/14.
   PubMed Web of Science ®Google Scholar
• Brown R, Turk F, Dale P, et al. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy. 2007;62:149–153. Epub 2007/02/15.
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364:1005–1015. Epub 2011/03/18.
   PubMed Web of Science ®Google Scholar
• Sorkness CA, Wildfire JJ, Calatroni A, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol Pract. 2013;1:163–171. Epub 2014/02/26.
   PubMed Web of Science ®Google Scholar
• Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136:1476–1485. Epub 2015/11/01.
   PubMed Web of Science ®Google Scholar
• Niven RM, Saralaya D, Chaudhuri R, et al. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). BMJ Open. 2016;6:e011857. Epub 2016/08/11.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest. 2004;125:1378–1386. Epub 2004/04/14.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804–811. Epub 2013/03/09.
   PubMed Web of Science ®Google Scholar
• Holgate ST. How to evaluate a patient’s response to anti-IgE. Eur Respir Rev. 2007;16:78–84.
   Google Scholar
• Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101:1483–1492. Epub 2007/03/07.
   PubMed Web of Science ®Google Scholar
• Standardization of Spirometry. Update. American Thoracic Society. Am J Respir Crit Care Med. 1994;1995(152):1107–1136.
   Google Scholar
• ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171:912–930.
   PubMed Web of Science ®Google Scholar
• Alving K, Janson C, Nordvall L. Performance of a new hand-held device for exhaled nitric oxide measurement in adults and children. Respir Res. 2006;7:67.
   PubMed Web of Science ®Google Scholar
• Menzies D, Nair A, Lipworth BJ. Portable exhaled nitric oxide measurement: comparison with the “gold standard” technique. Chest. 2007;131:410–414.
   PubMed Web of Science ®Google Scholar
• Tseliou E, Bakakos P, Kostikas K, et al. Increased levels of angiopoietins 1 and 2 in sputum supernatant in severe refractory asthma. Allergy. 2012;67:396–402.
   PubMed Web of Science ®Google Scholar
• Efthimiadis A, Spanevello A, Hamid Q, et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl. 2002;37:19s–23s. Epub 2002/10/04.
   PubMedGoogle Scholar
• Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59–99. Epub 2009/06/19.
   PubMed Web of Science ®Google Scholar
• Corren J. Role of interleukin-13 in asthma. Curr Allergy Asthma Rep. 2013;13:415–420. Epub 2013/09/13.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4:781–796. Epub 2016/09/13.
   PubMed Web of Science ®Google Scholar
• Jatakanon A, Kharitonov S, Lim S, et al. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax. 1999;54:108–114. Epub 1999/05/18.
   PubMed Web of Science ®Google Scholar
• Domingo C, Moreno A, Jose Amengual M, et al. Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients. Curr Med Res Opin. 2011;27:45–53. Epub 2010/11/19.
   PubMed Web of Science ®Google Scholar